Public Sector Pension Investment Board Takes Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Public Sector Pension Investment Board purchased a new stake in TransMedics Group, Inc. (NASDAQ:TMDX) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 70,566 shares of the company’s stock, valued at approximately $11,079,000.

Several other large investors also recently made changes to their positions in TMDX. International Assets Investment Management LLC bought a new stake in shares of TransMedics Group during the second quarter worth $47,000. USA Financial Formulas acquired a new position in TransMedics Group in the third quarter valued at about $55,000. J.Safra Asset Management Corp lifted its stake in TransMedics Group by 649.2% in the second quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock valued at $67,000 after buying an additional 383 shares during the period. Signaturefd LLC lifted its stake in TransMedics Group by 26.6% in the second quarter. Signaturefd LLC now owns 443 shares of the company’s stock valued at $67,000 after buying an additional 93 shares during the period. Finally, Farther Finance Advisors LLC lifted its stake in TransMedics Group by 187.0% in the third quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock valued at $76,000 after buying an additional 316 shares during the period. Institutional investors own 99.67% of the company’s stock.

Insider Buying and Selling

In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction on Monday, September 16th. The stock was sold at an average price of $153.42, for a total value of $1,323,247.50. Following the completion of the transaction, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at $9,457,269.06. The trade was a 12.27 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Edward M. Basile sold 6,750 shares of TransMedics Group stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total value of $563,962.50. Following the completion of the transaction, the director now directly owns 732 shares of the company’s stock, valued at $61,158.60. This represents a 90.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 26,958 shares of company stock valued at $3,470,328. Insiders own 7.00% of the company’s stock.

TransMedics Group Stock Performance

NASDAQ:TMDX opened at $87.11 on Friday. The stock has a market cap of $2.92 billion, a P/E ratio of 92.67 and a beta of 2.08. The stock has a 50 day simple moving average of $113.26 and a 200 day simple moving average of $136.45. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. TransMedics Group, Inc. has a 1-year low of $67.77 and a 1-year high of $177.37.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.17). The firm had revenue of $108.76 million for the quarter, compared to analyst estimates of $115.00 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The business’s revenue for the quarter was up 63.7% on a year-over-year basis. During the same period in the previous year, the business posted ($0.12) earnings per share. Research analysts anticipate that TransMedics Group, Inc. will post 1 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on TMDX shares. Needham & Company LLC reaffirmed a “hold” rating and set a $109.00 price target on shares of TransMedics Group in a research report on Friday, November 22nd. Robert W. Baird dropped their price target on TransMedics Group from $200.00 to $150.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 29th. TD Cowen dropped their price target on TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a research report on Monday, November 18th. Oppenheimer decreased their price objective on TransMedics Group from $200.00 to $125.00 and set an “outperform” rating for the company in a report on Tuesday, October 29th. Finally, Baird R W upgraded TransMedics Group to a “strong-buy” rating in a report on Tuesday, September 24th. Two research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $131.80.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.